Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Recce Pharmaceuticals Announces Positive Data Against Streptococcus Pneumoniae Sinusitis Infection in Animal Model

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

April 1, 2021

Recce Pharmaceuticals Ltd a company developing New Classes of Synthetic Anti-Infectives, is pleased to announce animal study data showing positive efficacy of a new anti-infective formulation RECCE® 111 (R111) against Streptococcus pneumoniae (S. pneumoniae) bacterial sinusitis in mice. RECCE® 111 is a non-descript title for an experimental compound, developed in-house, building upon the unique mechanisms of action of RECCE® 327.

  • Positive sinusitis infection data indicated in animal study
  • Study supports broad spectrum potential of Recce’s anti-infective compounds against Streptococcus pneumoniae (S. pneumoniae) for both nasal and intravenous administration
  • RECCE® 327 (R327) and experimental RECCE® 111 (R111) tested against marketed therapeutic alternative in-vivo in sinusitis study; independent study agreement anticipated

“We’re continually excited by the potential of Recce’s anti-infective compounds and are encouraged by these positive indications,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals. “Moreover, this further enhances the breadth of Recce’s synthetic polymer platform.”

The study was conducted by an independent Contract Research Organization, to assess the dose-dependency of R327 and R1111 in-vivo antibacterial activity against S. pneumoniae in a mouse model of acute bacterial rhinosinusitis infection.

Efficacy of Recce Anti-infectives in Acute Bacterial Rhinosinusitis Treatment Table
Group Treatment Clinical Observation
1 Early infection control (day1 post infection) NAD
2 Infection vehicle control, twice daily, oral, 5 days NAD
3 Positive Control (Azithromycin, oral, 200 mg/kg, twice daily, 5 days) NAD
4 RECCE® 327 (Low dose, Nasal, 50 mg/kg, Twice daily, 5 days) NAD
5 RECCE® 327 (Mid dose, Nasal, 100 mg/kg, Twice daily, 5 days) NAD
6 RECCE® 327 (High dose, Nasal, 500 mg/kg, Twice daily, 5 days) NAD
7 RECCE® 327 (Low dose, IV, 100 mg/kg, Twice daily, 5 days) NAD
8 RECCE® 327 (Mid dose, IV, 500 mg/kg, Twice daily, 5 days) NAD
9 RECCE® 327 (High dose, IV, 1000 mg/kg, Twice daily, 5 days) NAD
10 RECCE® 111 (Low dose, IV, 50 mg/kg, Twice daily, 5 days) NAD
11 RECCE® 111 (Mid dose, IV, 100 mg/kg, Twice daily, 5 days) NAD
12 RECCE® 111 (High dose, IV, 250 mg/kg, Twice daily, 5 days) NAD
Efficacy Acute Bacterial Rhinosinusitis
NAD: No abnormality detected

This bacterium was chosen due to its immediate availability as a recognized sinusitis model. Streptococcus pneumoniae, a Gram-positive bacterium, is a leading cause of bacterial pneumonia and meningitis in the United States, and a common cause of bloodstream infections, also known as sepsis, ear and sinus infections.2

A total of 12 groups of 10 mice each were assessed to determine the effectiveness of R327 and R111 against S. pneumoniae. Three groups were treated with varying intranasal doses twice daily of R327 (50, 100, 500 mg/kg) and showed a significant dose-dependent antibacterial effect when compared to early infection and vehicle control (p<0.05).

Three groups of mice were treated with varying intravenous doses of R327 (100, 500, 1,000 mg/kg) which showed significant dose-dependent antibacterial effect when compared to early infection control and vehicle control (p<0.05). Furthermore, three groups from the 12 were treated with varying intravenous doses of R111 (50, 100, 250 mg/kg) which showed a significant dose-dependent antibacterial effect when compared to early infection control and vehicle control (p<0.05).

Azithromycin was the positive control in the study given twice daily at 200 mg/kg and showed bactericidal effect when compared to vehicle control at five-days post infection (p<0.05).

The Company’s R327 and R111 compounds showed significant antibacterial capability with no abnormalities detected and are expected to be subject to further expanded sinusitis studies in due course. In addition to these studies, the Company’s clinical activities with R327 continues to progress in the background and looks forward to updating shareholders in due course.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine